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Background: Citrate has theoretical advantages over heparin for locking hemodialysis central venous catheters
(CVCs), but the comparative effectiveness of these agents is not clear.
Objectives: 1) To compare the benefits and harms of citrate versus heparin locking solutions among patients
undergoing hemodialysis through CVCs; 2) to appraise methodological quality of the supporting evidence.
Data sources: CENTRAL, MEDLINE, EMBASE, CINAHL, ISI Web of Science, and nephrology conference abstracts.
Study eligibility, participants, and interventions: We included randomized, parallel arm clinical trials that
enrolled adult patients (>18 years) receiving chronic hemodialysis through CVCs using a citrate locking solution.
We excluded studies in which citrate was combined with other agents, such as antibiotics.
Appraisal and synthesis methods: We used the GRADE approach to systematic reviews and quality appraisal.
Two reviewers performed data extraction independently and in duplicate. We pooled count data using generic
inverse variance with random-effects models, and used fixed-effect models when only two studies were available
for pooling. Subgroups included low (≤5%) vs. higher (≥30%) citrate.
Results: We screened 600 citations. Forty-one proceeded to full-text screen; 5 met inclusion criteria. Studies
included between 19 and 291 participants (Median N = 61) followed for a total of 174.6 catheter-years; 2 were
multi-centred trials. Three studies assessed all-cause mortality; the pooled relative risk for death was 0.71 (95%
CI = 0.42-1.24; p = 0.21; I2 = 0%). The rate ratio for bacteremic episodes was 0.54 (95% CI = 0.23-1.29; p = 0.16; I2 =
65%) while the rate ratio for bleeding was 0.48 (95% CI = 0.3-0.75; p = 0.001;I I2 = 5%). Rates of catheter exchange/
replacement, all-cause hospitalization and in-situ thrombolysis were not significantly different between groups in
any of the pooled analyses. Risk of bias within pooled studies was low.
Limitations: Outcome definitions varied across studies. Imprecision due to small sample sizes and low event rates
reduce our overall confidence in the pooled effect estimates.
Implications: Benefits and harms of citrate vs. heparin locking solutions remain unclear; larger studies and
standardization of outcome measurement and reporting are warranted.
Trial registration: Protocol Registration Number: CRD42013004781* Correspondence: gnesrallah@hrh.ca
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Contexte: En théorie, il appert que les solutions de citrate présentent certains avantages, comparativement aux
solutions héparinées, lorsqu’il s’agit du verrouillage des cathéters veineux centraux (CVC) utilisés en hémodialyse.
Cependant, l’efficacité relative de ces deux agents reste incertaine.
Objectifs de l’étude: 1) Comparer les avantages et les désavantages des solutions de verrouillage de citrate, d’une
part et d’héparine, d’autre part, chez les patients subissant des traitements d’hémodialyse par CVC, et 2) évaluer la
qualité méthodologique des données probantes.
Sources d’information: Les bases de données CENTRAL, MEDLINE, EMBASE, CINAHL, ISI Web of Science, et des
abrégés de communications à des conférences en néphrologie.
Admissibilité de l’étude, choix des participants et interventions: Nous avons tenu compte des essais cliniques
à répartition aléatoire à deux groupes, effectués sur des adultes (18 ans et plus) sous traitements réguliers
d’hémodialyse par CVC, et dont le verrouillage utilisait une solution de citrate. Les essais dont la solution de
verrouillage combinait le citrate à d’autres agents, comme des antibiotiques, ont été exclus.
Méthodes d’évaluation de la qualité de la preuve et de synthèse: Nous avons utilisé la méthode GRADE pour
analyser la qualité des données. Une extraction des données a été réalisée de manière indépendante par chacun
des deux évaluateurs. Nous avons regroupé les données de dénombrement en utilisant un modèle générique de
type « inverse variance with random-effect » et avons utilisé un modèle de type « fixed-effect » lorsque nous
n’avions que deux études à notre disposition. Les sous-groupes ont été divisés selon la concentration de citrate
dans la solution de verrouillage : basse (≤5%), ou élevée (≥30%).
Résultats: Nous avons passé 600 titres en revue. 41 d’entre eux menaient au texte plein écran; 5 rencontraient les
critères d’admissibilité. Le nombre de participants pour chaque étude se situait en 19 et 291 (médiane N = 61), pour
un total de 174,6 années-cathéter; 2 des études étaient des essais cliniques multicentres. Trois études avaient rendu
compte de toutes les causes de mortalité; la mesure combinée du risque relatif de mortalité était de 0,71 (95% IC =
0,42-1,24; p = 0,21; I2 = 0%). Le rapport de taux des bactériémies était de 0,54 (95% IC = 0,23-1,29; p = 0,16; I2 = 65%),
tandis que le rapport de taux des hémorragies était de 0,48 (95% IC = 0,3-0,75; p = 0,001; I2 = 5%). La variation dans
la fréquence de remplacement/changement du cathéter, d’hospitalisation (toutes raisons confondues) ou de
thrombolyse in situ n’était pas significative entre les différents groupes et ce, dans toutes les analyses combinées. Le
risque de biais à l’intérieur des études regroupées était faible.
Limites de l’étude: La définition des résultats variait selon l’étude. Notre confiance générale dans les estimations
regroupées est réduite puisqu’il existe certaines imprécisions résultant de petits échantillons et le taux
d’événements est faible.
Implications: Les avantages et désavantages de l’utilisation du citrate, comparativement à l’héparine, dans les
solutions de verrouillage restent incertains. Il serait justifié de procéder à des études plus vastes ainsi qu’à une
uniformisation de la mesure des résultats et des rapports.
Trial registration: Protocol Registration Number: CRD42013004781What was known before
Prior reviews have suggested that citrate-containing
antimicrobial locking solutions reduce the risk of
bacteremia. However, the quality of the supporting
evidence has not been extensively reviewed.What this adds
In this review, we focus on outcomes with citrate alone
versus heparin-based locking solutions for hemodialysis
catheters, and apply the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) ap-
proach to systematic reviews and evidence quality ap-
praisal. We identify a low overall quality of evidence
supporting a lower risk of bleeding, but no difference ininfection, hospitalization, or patency-related outcomes
with citrate versus heparin.Introduction
Despite guidelines, policies, and initiatives promoting
arterio-venous fistulae, prevalent central venous catheter
(CVC) rates persistently range between 10-50% internation-
ally, with upward trends in many high-income countries,
including Canada [1,2]. Catheter-related bacteremia re-
mains a common and potentially catastrophic hemodialysis
complication, resulting in significant morbidity and mortal-
ity, as well as hospitalization and resource use. Moreover,
thrombotic or patency-related complications reduce dialysis
adequacy, are costly, and result in treatment disruptions
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arin has been widely used as a locking solution, it is associ-
ated with a number of complications, including inadvertent
systemic administration with coagulopathy and bleeding
[3], heparin induced thrombocytopenia [4], and allergic re-
actions [5].
Citrate-based locking solutions are a promising alter-
native to unfractionated heparin, with a number of small
clinical trials recently evaluating its efficacy and safety.
Moreover, the unit cost for citrate has recently fallen to
below that of heparin in Canada and other jurisdictions,
making citrate a potentially cost-effective alternative.
Our aims were: 1) to conduct a systematic review and
meta-analysis to better understand the benefits and
harms of using citrate versus heparin as a CVC locking
solution, and 2) to appraise the quality of the supporting
body of evidence.Methods
Overview
Our review adhered to a pre-specified protocol, registered
with the PROSPERO register of systematic reviews (regis-
tration number: CRD42013004781) [6]. We used the Grad-
ing of Recommendations Assessment, Development and
Evaluation (GRADE) approach to systematic reviews and
methodological quality appraisal [7-10]. This manuscript
was prepared according to the PRISMA Guidelines [11].Study eligibility
Types of studies
We included randomized clinical trials and systematic
reviews published as full-text articles in peer-reviewed
journals, as well as abstracts presented at major nephrol-
ogy conferences. We excluded observational studies,
opinion pieces, narrative reviews, and any other articles
not containing original data.Types of participants
We included studies that enrolled adult patients (>18
years) with end-stage renal disease undergoing chronic
hemodialysis through CVC’s using a citrate locking solu-
tion (intervention) and heparin-based locking solutions
(control). Given major potential differences in disease
severity and treatment settings, we excluded studies of
inpatient or acute kidney injury populations, or those
admitted to intensive care units, or receiving continuous
renal replacement therapies. We also excluded studies in
which patients received hemofiltration or hemodiafiltra-
tion. We did not place any restrictions on catheter types
(tunneled vs. temporary), incident vs. prevalent patients,
or incident vs. prevalent catheters.Types of interventions
Experimental interventions consisted of citrate-based
catheter locking solutions – both low (4%) and higher (15-
50%) concentrations. The control intervention included
heparin or other non-citrate based locking solutions.
Types of outcomes
Critically important outcomes included patient survival
(all-cause mortality), bacteremia rates, and all-cause
hospitalization rates. Important but not critical out-
comes included access-related hospitalization, catheter
replacement/exchange events, bleeding, and local/in situ
thrombolysis (tPA, urokinase, or other), as measured by
number of thrombolytic administration episodes. We
used outcome definitions as they were described in the
included studies.
Information sources
We searched The Cochrane Central Register of Con-
trolled Trials (CENTRAL) [12], MEDLINE, EMBASE,
CINAHL and ISI Web of Science from inception to June
29, 2013.
Search
All search strategies were developed in collaboration
with a Health Information Specialist (NB), and included
the following headings and text words: population – dia-
lysis, hemodialysis; intervention – citrate, citric acid, so-
dium citrate; and comparator – heparin, other locking
solutions terms identified during pilot searches. A sam-
ple search strategy is in the web Additional file 1. We
did not restrict the search strategy based on outcome,
language or date of publication. Our primary search was
supplemented with hand-searches of narrative and sys-
tematic review bibliographies. We also searched confer-
ence abstracts from the Canadian Society of Nephrology
and the American Society of Nephrology annual meet-
ings spanning 2011–2013.
Study selection
We downloaded all identified reports into a reference
manager (Endnote X6 for Macintosh Thomson-Reuters
Inc., San Francisco, CA, USA). Two authors (AA and
AG) independently assessed all titles and abstracts for
relevance and eligibility for full-text screening. Only re-
ports that were obviously irrelevant were discarded.
Using the Distiller-SR online software tool [13], we de-
veloped a full-text screening form for study selection.
Disagreements concerning study inclusion were dis-
cussed until a consensus was reached.
Data collection process
Two reviewers (AA and AG) performed the data extraction
independently and in duplicate with the use of standard
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reasons for exclusion were documented for each of the ex-
cluded studies. Two reviewers assessed methodological
quality of the included studies. Discrepancies were resolved
by discussion, and if needed, a third reviewer (GN) was
consulted. No individual patient data was used.
Data items
For each included study, we extracted data on character-
istics of study participants, study design, details of inter-
ventions including drug concentration, outcomes (count
and rate data as applicable, with measures of dispersion),
and methodological factors affecting risk of bias and
other quality appraisal criteria.
Methodological quality appraisal
We applied the GRADE quality appraisal criteria [10].
These include risk of bias [14], indirectness (in popula-
tion, intervention or outcome) [15], imprecision [16], in-
consistency (heterogeneity) [17], and publication bias
[18]. Risk of bias in individual studies was assessed accord-
ing to the criteria proposed by Higgins et al., including
adequacy of sequence generation, allocation concealment,
blinding of participants, outcome assessors, and study
personnel, completeness of follow-up, and selective out-
come reporting [19].
Summary measures and synthesis of results
All analyses were performed using RevMan 4.3 for Mac-
intosh. We used random effects models to compute rate
ratios, but used fixed-effects models when only two
studies were available for pooling [20]. We assessed het-
erogeneity using the I2 statistic.
Additional analyses
Where possible, we performed (pre-specified) subgroup
analyses according to citrate concentration, using cut-
points defined by included studies (<5% or >30%).
Results
Study selection
We identified a total of 600 studies (Figure 1), including
111 in Medline, 31 in CINAHL, 268 in EMBASE, 31 in
CCTR and 159 in Web of Science. We did not identify
any relevant conference abstracts. We identified and re-
moved duplicate records (N = 252). Forty-one studies
proceeded to full-text screening. Reasons for exclusion
were: no original data (including systematic reviews)
(N = 33), study population did not consist of outpa-
tients receiving chronic hemodialysis through central
venous catheters (N = 2), and crossover design (N = 1).
Five studies were therefore included in our review
[21-25].Study characteristics
All 5 included studies were parallel-arm randomized tri-
als (Table 1). Studies included between 19 and 291 par-
ticipants (median = 61), followed for a total of 176.4
catheter-years, with study population mean age ranging
between 62 to 75 in citrate treatment groups and be-
tween 61 to 71 in heparin treatment groups, and per-
centage of female patients ranging from 34 to 60 in
citrate treatment groups and from 41 to 56 in heparin
treatment groups. Studies were conducted in Canada,
the Unites States, Europe, and Asia; two of the studies
were multi-centered [23].Results of individual studies
Event rates for individual studies are in Table 2. Follow-
up ranged between 1,703 and 19,008 catheter days
for citrate treatment groups, and between 1,493 and
17,100 catheter days for heparin treatment groups across
studies.Synthesis of results
Forest plots and details of pooled estimates are in
Figures 2, 3, 4, 5, 6 and Table 3. Three studies re-
ported all-cause mortality, with a pooled relative risk
of 0.71 (95% CI = 0.42-1.24; p = 0.21; I2 = 0%) favouring
citrate over heparin. Three studies assessed bacteremic
episodes; the rate ratio for this outcome was 0.54 (95%
CI = 0.23-1.29; p = 0.16; I2 = 65%) favouring citrate
over heparin. Bleeding was reported in two studies,
with a rate ratio of 0.48 (95% CI = 0.3-0.75; p = 0.001;
I2 = 5%), favouring citrate over heparin. Rates of cath-
eter exchange/replacement and in-situ thrombolysis
were not significantly different between groups in any
of the pooled analyses. Finally, the pooled rate ra-
tio for all-cause hospitalization was 0.68 (95% CI =
0.38-1.20; p = 0.18; I2 = 86%), favouring citrate over
heparin.Methodological quality appraisal
Table 3 summarizes the quality appraisal for pooled es-
timates on an outcome-by-outcome basis. Risk of bias
was low in all included studies. One study was open-
label, but due to the nature of the reported outcomes,
unblinding was unlikely to result in a significant risk of
bias [23]. A small overall number of included studies
precluded any meaningful analysis of publication bias
by funnel plots. Despite a low risk of bias within in-
cluded studies, the overall quality of evidence was low
for both critical and important outcomes, with incon-
sistency (heterogeneity) and imprecision (due to small
sample sizes) affecting the quality of the majority of
estimates.
Figure 1 Study inclusion flow diagram.
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We created subgroups according to citrate concentra-
tion (<5% vs. >30%). However, given the small overall




Compared with heparin, citrate catheter locking solu-
tions were associated with significantly fewer bleedingepisodes. Rates of death and bacteremia tended to be
lower with citrate, but pooled effect estimates were not
statistically significant. No significant differences in cath-
eter exchange/replacement, thrombolysis, or all-cause
hospitalization were evident between groups in any of
the pooled analyses.
Our findings are consistent with those of a similar
and recently published meta-analysis by Zhao et al.,
which also found significantly reduced bleeding rates,
but no difference in survival, hospitalization, or
Table 1 Characteristics of included studies
Source Country
(#Centres)
Study duration N Methods Participants Intervention Control Outcomes Funding Source
[22] Slovenia (1) Not
specifically
stated.
30 Method of randomization
unclear.
ESRD patients with subclavian
or jugular single lumen
catheters inserted as
temporary blood accesses for
HD expected to be used for at
least 7 days.
3 ml of 4% trisodium
citrate
A mixture of 1 ml
(5000 U/ml) of
unfractionated
heparin and 2 ml
of saline.
Catheter removal. Not specified.
[23] Belgium (1) April 2000 -
October 2000
19 Method of randomization
unclear.
Chronic hemodialysis patients
with a single lumen central
venous catheter as permanent
vascular dialysis access.
5% trisodium citrate 5000 U/ml heparin
solution
Local/in-situ thrombolysis
(bolus events for inadequate
blood flow).
Not specified.
[24] Canada (1) December
2004 - June
2005
61 Randomization based on
patient surnames.
All patients receiving chronic
HD three times a week, 4 h/
session, at the in-center
Hemodialysis Unit with cuffed
catheters as primary vascular
access were eligible for the
trial.





















ESRD patients with IJ CVCs
(Bio-Flex TC), on HD > 90 days.
46.7% trisodium
citrate.














Patients >18 years, not
admitted to the intensive care
ward, with chronic or acute
renal failure that required
hemodialysis through a CVC.
Only patients with a newly
inserted, well-positioned CVC










removal rates, and catheter
treatment with urokinase.
Not specified.
















Table 2 Rates of events in individual studies
Study Citrate Heparin
Events Catheter days Events/1000 catheter days Events Catheter days Events/1000 catheter days
Mortality
Power 5 19008 0.26 5 17100 0.29
Weijmer 13 8181 1.59 18 8049 2.24
MacRae 4 2272 1.76 5 1818 2.75
Bacteremia
Power 13 19008 0.68 12 17100 0.70
Weijmer 9 8181 1.10 33 8049 4.10
MacRae 5 2272 2.20 6 1818 3.30
Access-related hospitalization
Power 17 19008 0.89 12 17100 0.70
Weijmer 6 8181 0.70 21 8049 2.70
Catheter replacement
Buturovic 1 2272 1.96 1 1818 4.35
MacRae 8 2272 3.52 5 1818 2.75
Weijmer 27 8181 3.21 29 8049 3.56
Thrombolysis
MacRae 13 2272 5.72 13 1818 7.15
Power 1 19008 0.06 1 17100 0.04
Weijmer 69 8181 8.28 63 8049 7.88
Bleeding
MacRae 25 2272 11.00 37 1818 20.35
Weijmer 5 8181 0.60 16 8049 2.00
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heparin [26]. The review by Zhao et al. also included
studies in which citrate was combined with various
antimicrobial agents, including gentamicin, taurolidine,
methylene blue, and methylparaben, yielding a pooled
rate ratio of 0.39 (95% CI = 0.27 to 0.56; I2 = 27%) forFigure 2 Comparative risk of death (all-cause) with citrate vs. heparincatheter-related bloodstream infection, favouring
citrate-containing locking solutions over heparin. Their
findings are corroborated by two other similar reviews
[27,28]. Given the small overall number of studies com-
paring the effects of citrate alone versus heparin (N = 3)
on bacteremia rates, neither our study, nor that of Zhaolocking solutions.
Figure 3 Comparative risk of bacteremia with citrate vs. heparin locking solutions.
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Whether the protective effect of citrate on blood-
stream infection rates noted by Zhao et al. is a result of
greater statistical power due to the inclusion of more
studies, or attributable to the secondary antimicrobial
agents included in these study interventions is unclear.
Larger studies would be needed to confirm whether or
not citrate alone confers a benefit similar to that of
citrate-based locking solutions containing additional
antimicrobial agents.
Plausible biological mechanisms exist by which citrate
alone might reduce systemic infections when instilled in
catheter ports. In vitro studies have demonstrated bac-
tericidal and sporocidal activity with both high (23%)
and lower (4%) citrate concentrations, and prevention of
biofilm formation, with no evidence of citrate resistance
[29,30]. This is in contrast to heparin, which may in fact
promote biofilm formation and increase infection risk
[31,32]. Citrate’s antibacterial activity appears to be re-
lated to the chelation of calcium and magnesium ions,
leading to the degradation of bacterial cell membranes,
thus reducing bacterial cellular integrity [33]. Given its
avidity for divalent cations, inadvertent systemic admin-
istration of large volumes of citrate locking solutions
can result in calcium complexation and hypocalcemia.
One report described a fatal outcome associated withFigure 4 Comparative risk of bleeding with citrate vs. heparin lockinghigh concentration citrate (46.7%) administration; this
ultimately led to FDA and Health Canada bans on
highly concentrated citrate locks in the US and Canada
[34]. Our review did not identify any evidence of harm
due to inadvertent systemic administration with the cit-
rate concentrations used in included studies, and in
current routine use [23].
We observed a significantly lower rate of bleeding
with citrate as compared with unfractionated heparin
(Figure 4). Although the magnitude of effect was simi-
lar in the two studies included in this pooled estimate,
the event rates were vastly different (~10-fold differ-
ence in control group event rate; Table 2), suggesting
differences in study populations, co-interventions, and
outcome definitions. Assuming that bleeding risk at-
tributable to locking solutions is due to occasional in-
advertent systemic administration, it seems reasonable
to conclude that the anticoagulant effect of citrate in
these two studies (4% and 30%) was lower in vivo than
were similar volumes of unfractionated heparin at 5000
IU/ml.Limitations
We included only randomized trials focusing on patient-
important outcomes, and performed a rigoroussolutions.
Figure 5 Comparative risk of CVC replacement for impaired patency with citrate vs. heparin locking solutions.
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approach. Nevertheless, some additional factors limit
our overall confidence in the observed pooled estimates.
A small overall number of included studies, small
sample sizes within studies, and low event rates limit
the precision of most of the pooled analyses. We also
found some heterogeneity in the pooled estimate for
bacteremia, but a small overall number of studies pre-
cluded any meaningful subgroup analyses. We also could
not exclude publication bias.Implications for practice
Compared with unfractionated heparin, citrate catheter
locking solutions appear to reduce bleeding, and may re-
duce bacteremia in patients undergoing hemodialysis
with a CVC. However, it is unclear from the current
published evidence whether citrate alone has the same
protective effect against systemic infection as it does
when combined with other antimicrobial agents, as ob-
served in the review by Zhao et al. [26]. Although the
overall quality of evidence supporting its use is low, both
The American Society of Diagnostic and Interventional
Nephrology (ASDIN) and European Renal Best Practice
(ERBP) consider 4% citrate and heparin acceptable alter-
natives for locking CVCs [35,36]. Given the availability
of 4% citrate in prefilled syringes, and lower unit costs
when compared with unfractionated heparin, citrate mayFigure 6 Comparative risk of hospitalization (any cause) with citrate vbe the preferred choice, especially if differences in cost
increase over time.Implications for research
Studies comparing citrate with unfractionated heparin-
based catheter locking solutions have generally been
small and not adequately powered to provide con-
clusive evidence of safety and efficacy; hence, larger
comparative trials are desirable. Moreover, with the in-
creasingly favourable safety profile and falling costs of
low molecular weight heparins, studies comparing these
agents with citrate would be useful in informing prac-
tice as well. Although not in widespread use, recombin-
ant tissue plasminogen activator (rt-PA) has been used
weekly for locking dialysis catheters, with cost effective-
ness comparable to that of heparin (costs of rt-PA off-
set by reduced hospitalization for bacteremia) [37,38].
Future studies comparing the effectiveness of rt-PA
with that of citrate might also be of interest. Finally,
we, and others have noted significant variability in out-
come definitions in hemodialysis vascular access studies
[39]. This represents a potential source of heterogeneity
and renders the overall body of evidence less amenable
to meaningful quantitative synthesis. Standardization of
outcome reporting in vascular access research is needed,
and published outcome definitions now make this pos-
sible [40].s. heparin locking solutions.
Table 3 GRADE evidence profile table: citrate vs. heparin locking solutions for hemodialysis catheters











Survival (follow up: range 56,428 Total Catheter Days)
3 randomised
trials




RR 0.71 (0.42 to
1.21)
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Bacteremia (follow up: range 56,428 Total Catheter Days)
3 randomised
trials






0 fewer per 1000 (from 0




Thrombolysis (follow up: range 56,428 Total Catheter Days)
3 randomised
trials






0 fewer per 1000 (from 0




Bleeding (follow up: range 20,320 Total Catheter Days)
2 randomised
trials






0 fewer per 1000 (from 0




Hospitalization for any reason (follow up: range 52,338 Total Catheter Days)
2 randomised
trials






0 fewer per 1000 (from 0




Catheter replacement for patency (follow up: range 24,410 Total Catheter Days)
3 randomised
trials






0 fewer per 1000 (from 0




MD – mean difference, RR – relative risk.
1Studies not powered for survival outcome; optimal information siz e criterion not met.
2I2=65% for pooled effect estimate; could not exclude heterogeneity due to study design, duration of follow-up, and citrate concentration.
3Overall event rates were low; studies were likely underpowered to detect statistically significant differences in bacteremia.
4I2=77% for pooled effect estimate, possibly due to unexplained heterogeneity in outcome definitions and study design.
5Vary small event rate and sample siz e; observed effect may be due to random error.
6I2=86% using fixed-effect model; unexplained heterogeneity exists.
7Confidence interval includes no effect.
8Optimal information siz e criterion not met.
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